IQUO ANDREWS-COOPER: Open Payments
NPI 1992182117 · ABERDEEN, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$558 in 31 payments from 9 companies in 2025. Trend: 2023 $622 · 2024 $546 · 2025 $558
Food & beverage: $558
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $201 |
| Teva Pharmaceuticals USA, Inc. | 4 | $81 |
| Neurocrine BioSciences, Inc. | 3 | $70 |
| Otsuka America Pharmaceutical, Inc. | 3 | $63 |
| Vanda Pharmaceuticals Inc. | 2 | $42 |
| E.R. Squibb & Sons, L.L.C. | 1 | $37 |
| Janssen Pharmaceuticals, Inc | 1 | $24 |
| Alkermes, Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
Products named: VRAYLAR, INGREZZA, HETLIOZ, ABILIFY MAINTENA, AUSTEDO XR, UZEDY, COBENFY, INVEGA SUSTENNA.
Industry payments across MD — which companies pay providers there.
